Recent Updates
Recently added Catalysts
CTNM Positive Sentiment

Qureight’s Fibrosis Imaging Biomarker Selected by Contineum Therapeutics as a Secondary Endpoint in Phase 2 PROPEL-IPF Clinical Trial

Monday, November 9, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Qureight's Fibr8™ imaging biomarker has been chosen by Contineum Therapeutics as a secondary endpoint in the Phase 2 PROPEL-IPF clinical trial. This collaboration aims to address significant unmet needs in the treatment of inflammatory and fibrotic diseases. The trial will leverage Qureight's advanced imaging capabilities to enhance clinical outcomes.

Market Sentiment Analysis

POSITIVE FACTORS

  • Qureight's biomarker selected for a Phase 2 trial.
  • Collaboration with Contineum Therapeutics announced.
  • Focus on significant unmet needs in fibrotic diseases.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+63%
120-day peak, hindsight
Typical move
2.8%
average across 4 past catalysts
Cash runway
~66 mo
Minimal dilution risk
Lead asset
PIPE-307
Phase 2 · Relapsing Remitting Multiple Sclerosis

Full Press Release Details

CAMBRIDGE, England & SAN DIEGO--(BUSINESS WIRE)--Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, and Contineum Therapeutics, Inc. (Contineum) (NASDAQ:CTNM), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that Qureight’s Fibr8™ quantitative imaging biomarker is being us

Frequently Asked Questions

What is Qureight's Fibr8™ biomarker?

Fibr8™ is a quantitative imaging biomarker developed by Qureight for clinical trials.

Which company selected the Fibr8™ biomarker?

Contineum Therapeutics selected Qureight's Fibr8™ biomarker for its clinical trial.

What is the purpose of the PROPEL-IPF trial?

The trial aims to evaluate treatments for idiopathic pulmonary fibrosis.

What type of diseases does Contineum focus on?

Contineum focuses on inflammatory and fibrotic diseases with unmet needs.

ShareAdd on Google
Tags: CTNM Qureight Contineum Therapeutics Phase 2 trial biomarker fibrotic diseases
Last updated: Nov 9, 2026

Biotech snapshot

Cash runway
$244M liquidity · $4M/mo burn
~66 mo
Minimal dilution risk
Lead asset
PIPE-307Phase 2
Relapsing Remitting Multiple Sclerosis →

Catalyst track record

+63%
best trade around CTNM's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for CTNM.

See every catalyst's timing & PoA →